comparemela.com

Davidl Rimm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact?

One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels "is like weighing mice on a scale built for elephants," says one expert.

United statesDana farber cancer instituteNew havenSaram tolaneyGiuseppe curiglianoAnthonyn bradyDavidl rimmInnovative therapies divisionYale school of medicineAmerican society of clinical oncologyDivision of breast oncologySusanf smith centerEuropean institute of oncologySan antonio breast cancer symposiumYale schoolSeperate clinical entity

New path to treat advanced triple-negative breast cancer

A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or

Keisuke aoshimaXuanlin cheMeiling zhangYao liJocelynf chenTianrui xuZongzhiz liuAsako aoshimaWesleyl caiQin yanHongyin sunDavidl rimmSaraj rutterVeerle bossuytAxiang chenZhenwei tang

vimarsana © 2020. All Rights Reserved.